【佳学基因检测】CCDC137表达的预后意义及其与肝细胞癌免疫浸润的关系

上海肿瘤基因检测机构机会

参加学术会议时了解《Dis Markers》在. 2022 Aug 24;2022:5638675.发表了一篇题目为《CCDC137表达的预后意义及其与肝细胞癌免疫浸润的关系》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Lu Bai, Zhao-Xu Yang, Jian-Shan Liu, De-Sheng Wang, Heng-Chao Yu 等完成。促进了肿瘤的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

在全球范围内，肝细胞癌 (HCC) 是癌症相关死亡的贼常见原因之一。由于远处转移和反复，HCC患者的临床结果仍然很差。近年来，越来越多的证据证实含有卷曲螺旋结构域（CCDC）的家族蛋白参与了多种疾病的进展。然而，尚未研究包含卷曲螺旋结构域的 137 (CCDC137) 在肝细胞癌 (HCC) 中的表达和临床意义。在 TCGA-LIHC 中获得了 3 级 mRNA 表达谱和临床病理学数据。在 371 个 HCC 和 50 个非肿瘤样本之间筛选了差异表达基因 (DEG)。在 HCC 患者中分析了 CCDC137 的预后价值。研究了 CCDC137 与癌症免疫浸润之间的相关性。本研究共获得2897个DEG：2451个基因显着上调，446个基因显着下调。 KEGG 分析显示这些 DEG 参与了肿瘤进展。在 2897 个 DEG 中，我们发现与非肿瘤标本相比，HCC 标本中 CCDC137 的表达明显增加。高水平的 CCDC137 表达与晚期肿瘤分期和分级有关。此外，与 CCDC137 水平较低的患者相比，CCDC137 表达水平较高的患者的总生存期和无病生存期较短。 CCDC137 表达与几种免疫细胞的浸润水平呈正相关，例如 CD8 T 细胞和 Th2 细胞。贼后，体外实验证实CCDC137在HCC细胞中高表达，其敲低抑制了HCC细胞的增殖。总之，我们的研究结果表明，CCDC137 可用作 HCC 免疫浸润和预后不良的生物标志物，这为 HCC 的潜在疗法提供了新的见解。

肿瘤发生与反复转移国际数据库描述：

Globally, hepatocellular carcinoma (HCC) is one of the most common causes of cancer-associated mortalities. The clinical outcome of HCC patients remains poor due to distant metastasis and recurrence. In recent years, growing evidences have confirmed that the coiled-coil domain-containing (CCDC) family proteins are involved in the progression of several diseases. However, the expression and clinical significance of the coiled-coil domain-containing 137 (CCDC137) in hepatocellular carcinoma (HCC) have not been investigated. Level 3 mRNA expression profiles and clinicopathological data were obtained in TCGA-LIHC. Differentially expressed genes (DEGs) were screened between 371 HCC and 50 nontumor specimens. The prognostic value of CCDC137 was analyzed in HCC patients. The correlations between CCDC137 and cancer immune infiltrates were investigated. In this study, a total of 2897 DEGs were obtained: 2451 genes were significantly upregulated and 446 genes were significantly downregulated. KEGG assays revealed that these DEGs were involved in tumor progression. Among 2897 DEGs, we found that CCDC137 expression was distinctly increased in HCC specimens compared with nontumor specimens. A high level of CCDC137 expression was related to an advanced tumor stage and grade. Moreover, patients with higher levels of CCDC137 expression had a shorter overall survival and disease-free survival than patients with lower CCDC137 levels. CCDC137 expression was positively correlated with infiltrating levels of several immune cells, such as CD8 T cells and Th2 cells. Finally, in vitro experiments confirmed that CCDC137 expression was highly expressed in HCC cells, and its knockdown suppressed the proliferation of HCC cells. Taken together, our findings revealed that CCDC137 might be used as a biomarker for immune infiltration and poor prognosis in HCC, which offered fresh insight on potential therapies for HCC.